Article Abstract

What does the Acute Respiratory Distress Syndrome trial (ART) teach us?—it is time for precision medicine and precision trials in critical care!

Authors: Jacopo Fumagalli, Lorenzo Berra


Acute respiratory distress syndrome (ARDS) affects a remarkable proportion of patients admitted to the intensive care unit (ICU) and according to a recent international survey, mortality attributable to ARDS remains high (≈40%) (1).